U.S. Life Sciences Stock News

Biogen (NasdaqGS:BIIB) received FDA Breakthrough Therapy Designation for salanersen, an investigational once-yearly treatment for spinal muscular atrophy (SMA). The designation is based on clinical data that the FDA views as potentially meaningful for patients with SMA. This marks a fresh regulatory milestone for Biogen that is separate from its previously covered lupus and Parkinson's programs. For investors tracking Biogen at a share price of $196.45, the salanersen news adds a new angle...

C3.ai (AI) just posted its FY 2026 fourth quarter numbers, with revenue at US$51.6 million and a basic EPS loss of US$0.79, alongside a trailing 12 month revenue base of US$250.3 million and a trailing EPS loss of US$3.35. Over recent quarters, the company has seen quarterly revenue move from US$108.7 million in Q4 FY 2025 to US$51.6 million in Q4 FY 2026, while quarterly basic EPS losses ranged between US$0.60 and US$0.94. This sets up an earnings print where the focus is firmly on how...

What Upwork’s New Board Appointments Could Mean for Investors Upwork (UPWK) has drawn fresh attention after appointing Claire Bramley and David Lissy to its Board of Directors, both joining the Audit, Risk, and Compliance Committee following the June 4, 2026 stockholder meeting. For you as an investor, this kind of board refresh is less about headlines and more about what it could imply for oversight of finances, risk, and long term decision making at a company that sits at the center of...

The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 16% annually. For investors willing to look beyond the big names, penny stocks can present intriguing opportunities for growth at lower price points. While often associated with smaller or newer companies, these stocks can offer potential upside when backed by strong fundamentals and sound balance sheets.

Over the last 7 days, the United States market has remained flat, yet it is up 26% over the past year with earnings expected to grow by 16% per annum over the next few years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and strong potential to capitalize on future market trends.

The United States market has shown a remarkable 26% increase over the past year, despite remaining flat over the last week, with expectations for earnings to grow by 16% annually in the coming years. In this context, identifying stocks that are potentially undervalued can be crucial for investors seeking opportunities that align with these growth prospects and current market stability.

The United States market remained flat over the last week but has seen a robust 26% increase over the past year, with earnings expected to grow by 16% annually. In such an environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong internal confidence and alignment of interests between management and shareholders.

The United States market has remained flat over the last week but is up 26% over the past year, with earnings expected to grow by 16% annually. In this context of robust growth expectations, dividend stocks can offer a compelling blend of income and potential capital appreciation, making them an attractive option for investors seeking stability and returns.

Wondering whether Tenable Holdings at around US$29.29 is starting to look like value, or if the stock still carries more risk than reward. The share price has moved sharply in the short term, with returns of 12.9% over the past week and 39.3% over the past month, while year to date the stock is up 28.9%. However, it has fallen 10.0% over the past year, 26.5% over three years and 31.9% over five years. Recent coverage has focused on Tenable Holdings as a cybersecurity platform provider, with...

Membership expansion sets the stage for recurring revenue focus Six Flags Entertainment (FUN) is extending its Membership program to six more parks starting June 8, giving guests broader multi park access with low monthly payments and putting recurring revenue squarely in focus. For you as an investor, this type of membership expansion matters because it shifts more of the company’s business toward ongoing payments, rather than relying solely on individual ticket sales or seasonal spikes in...

Securities law firm announces investigation into Via Transportation (NYSE:VIA) for potential securities law violations. Focus of the probe is on whether Via Transportation made inaccurate statements about its financials and business operations. Investigation could have implications for current and prospective shareholders depending on its findings. Via Transportation, listed on the NYSE under ticker VIA, operates in the technology enabled transit and mobility services space, connecting...

Kodiak Sciences (NasdaqGM:KOD) reported positive phase III results for its drug candidate Zenkuda in diabetic retinopathy. The company is accelerating regulatory submissions following the data readout, aiming to move the program toward potential approval. Kodiak Sciences is drawing fresh attention after this clinical update, with the stock at $34.16 and up strongly year to date, including a very large gain over the past 1 year. At the same time, shares are down 5.4% over the past week and...

If you are wondering whether Kenvue's current share price offers value, or if you are better off waiting on the sidelines, this article breaks down what the market is pricing in and how that compares with several valuation checks. The stock recently closed at US$16.88 and has fallen 4.3% over the last week, 2.8% over the last month, and 2.5% year to date. The return over the past year is down 18.4% and down 24.1% over three years. Recent news flow around Kenvue has focused on its position as...

Stock performance snapshot and recent context Vertex Pharmaceuticals (VRTX) has drawn investor attention after recent trading left the stock with a 1 day gain of about 3.1%, while returns over the past 3 months show a decline of roughly 3.3%. See our latest analysis for Vertex Pharmaceuticals. That move comes on top of a 4.1% 1 month share price return and a 1 year total shareholder return that is roughly flat, while the 5 year total shareholder return above 100% points to stronger long term...

Some Axon Enterprise, Inc. ( NASDAQ:AXON ) shareholders may be a little concerned to see that the COO & CFO, Brittany...

If you are wondering whether Allison Transmission Holdings at around US$118 a share still offers value, the starting point is understanding what the current price is really baking in. The stock has been volatile recently, with a 4.3% gain over the last week, a 7.1% decline over the last month, and returns of 19.6% year to date and 16.8% over the past year that may catch your eye. These moves sit against a backdrop of ongoing interest in capital goods companies and how investors are pricing...

SunPower’s equity and debt moves SunPower (SPWR) has moved to close a US$40.7 million shelf registration and is now seeking to pay upcoming interest on its 2029 convertible notes in stock plus bonus shares instead of cash. This combination of equity capacity, proposed share-based interest payments, and a recent incremental investment from Fortis Capital is intended to give the company more room to manage liquidity through Q3 2026. See our latest analysis for SunPower. Recent announcements...

In recent days, Conagra Brands reported quarterly results with slightly lower year-over-year revenue that still exceeded analyst expectations, alongside mixed profit guidance affected by commodity cost pressures. At the same time, several analysts warned that persistent inflation and a high payout ratio could put Conagra’s dividend policy under scrutiny, even as insiders accepted additional equity awards. We’ll now examine how concerns about inflation-driven cost pressures and potential...

Clinical data catalyst and recent stock move Enliven Therapeutics (ELVN) is back in focus after the company highlighted upcoming Phase 1 ENABLE trial data for ELVN-001 in chronic myeloid leukemia, set to be presented at the European Hematology Association Congress. The company plans a June 11 webcast to walk through the updated results. This, together with recent positive analyst commentary, has drawn fresh attention to a stock that is up 66.1% over the past year. See our latest analysis for...

If you are wondering whether Microchip Technology at around US$96.30 is still offering value or if the easier gains are behind it, this breakdown will help you weigh what the current price really implies. The stock is roughly flat over the past week with a 0.3% gain, a little softer over the last month with a 2.2% decline, yet stands out with returns of 48.1% year to date and 53.7% over the past year. Recent coverage has focused on Microchip Technology's role within the broader semiconductor...

OneMain Holdings (NYSE:OMF) has launched its first consumer loan asset backed securities securitization of 2026. This transaction is the company's 32nd consumer loan ABS issuance since 2013. The new deal has attracted ratings coverage, adding a fresh data point for investors tracking OneMain's funding mix. For investors watching consumer finance, OneMain sits at the intersection of personal lending and structured credit. The company uses consumer loan ABS as a recurring funding tool. The...

Veeva Systems (VEEV) kicked off Q1 2027 with revenue of US$882.9 million and basic EPS of US$1.60, against a backdrop of trailing 12 month EPS of US$5.75 and total revenue of about US$3.3 billion that has been reported growing around 11.2% year over year. Over recent quarters, revenue has moved from US$759.0 million in Q1 2026 through US$835.9 million in Q4 2026 to US$882.9 million in Q1 2027, while basic EPS has shifted from US$1.40 to US$1.49 and then to US$1.60 over the same period,...

Nvidia CEO Jensen Huang’s recent GTC Taipei keynote at Computex, which reframed the scale and duration of the AI chip cycle and confirmed its next data center platform, has renewed interest in AI-related semiconductor suppliers such as Allegro MicroSystems. This matters because Allegro’s exposure to automotive, industrial and data center power and sensing solutions ties its longer-term prospects more closely to how far AI infrastructure spending extends beyond core GPUs. With Allegro...

Cognyte Software (CGNT) opened Q1 2027 with revenue of US$105.5 million and a basic EPS loss of US$0.04, while the trailing twelve months show revenue of US$410.0 million and a basic EPS loss of US$0.04. Over recent quarters, revenue has moved from US$95.5 million in Q1 2026 to US$105.5 million in Q1 2027, as quarterly EPS has swung between a loss of US$0.07 and a profit of US$0.05. This sets up a picture where investors are likely to focus squarely on how the current loss profile is...